Table 5.
The efficacy of aliskiren in heart failure
| Outcome | No. of SRs | No. of original studies | No. of cases/controls | Follow-up range (weeks) | Type of metric | Estimate (95%CI) | P-value | 95%PI | I2(P*) | Egger’s P value |
|---|---|---|---|---|---|---|---|---|---|---|
| aliskiren vs placebo | ||||||||||
| NT-proBNP levels | 1 | 3 | 975/956 | 12–48 | SMD | −0.12 [−0.21,-0.03] | 0.01 | [−0.70,0.46] | 0% (0.57) | 0.814 |
| BNP levels | 1 | 2 | 151/143 | 6–12 | SMD | −0.08 [−0.31,0.15] | 0.49 | NA | 0%(0.76) | NA |
| Plasma renin activity | 1 | 3 | 176/157 | 12–48 | SMD | −0.66 [−0.89,-0.44] | < 0.0001 | [−2.11,0.77] | 0%(0.85) | 0.648 |
| Plasma renin concentration | 1 | 2 | 167/149 | 6–26 | SMD | 0.52 [0.30,0.75] | < 0.0001 | NA | 0%(0.72) | NA |
| Aldosterone level | 1 | 2 | 151/143 | 6–12 | SMD | −0.09 [−0.32,0.14] | 0.44 | NA | 0%(0.55) | NA |
| Mortality | 2 | 3 | 1255/1250 | ≥12 | RR | 0.76 [0.32–1.80] | 0.53 | [0.00,3273.53] | 24%(0.27) | 0.498 |
| Myocardial infarction | 1 | 1 | 305/308 | 104 | RR | 0.13[0.02–1.00] | 0.05 | NA | NA | NA |
| Stroke | 1 | 1 | 305/308 | 104 | RR | 0.25 [0.03–2.25] | 0.22 | NA | NA | NA |
| aliskiren vs enalapril | ||||||||||
| Combined cardiovascular mortality and hospitalisation | 1 | 1 | 2340/2336 | 36 | RR | 0.98 [0.90–1.06] | 0.57 | NA | NA | NA |